Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100000, China.
Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing 100000, China.
Neural Plast. 2021 Aug 28;2021:6718184. doi: 10.1155/2021/6718184. eCollection 2021.
Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone ( = 0.3232, = 0.001). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204-1.842, < 0.0001). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.
已经提出了几种临床参数和生物标志物作为中风的预后标志物。然而，尚未明确影响复发性和首次中风患者预后的危险因素是否相似。在这项研究中，我们旨在探讨可溶性凝集素样氧化低密度脂蛋白受体 1（sLOX-1）水平与复发性和首次中风患者功能结局预测之间的关系。共纳入 266 例复发性和首次中风患者，对其进行了 3 个月的随访。在发病后 24 小时内采集血浆样本。结果表明，复发性中风患者的预后生物标志物与首次中风患者不同。sLOX-1 水平与复发性中风患者改良 Rankin 量表评分相关（ = 0.3232， = 0.001）。sLOX-1 水平也与复发性中风患者不良结局的风险增加相关，调整后的优势比为 1.489（95%置信区间，1.204-1.842， < 0.0001）。结合危险因素对预后具有更高的准确性，ROC 曲线评估的曲线下面积为 0.916，敏感性为 93.2%，特异性为 75%。这些发现表明，复发性中风患者和首次中风患者的诊断和预后不同，sLOX-1 水平是复发性中风患者的独立预后标志物。
